Evidence map›Paper›PMID 40215705›Full record

ArticleVaccine2025

Development and validation of a clinical prediction tool for non-receipt of updated COVID-19 vaccines.

Katia J Bruxvoort, Lina S Sy, Richard Contreras, Bruno Lewin, Vennis Hong, Lei Qian, Kimberly J Holmquist, Bing Han, Stanley Xu

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katia J BruxvoortDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL 35233, United States; Department of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles Ave, 5th Floor, Pasadena, CA 91101, United States. Electronic address: kbruxvoort@uab.edu.
Lina S SyDepartment of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles Ave, 5th Floor, Pasadena, CA 91101, United States.
Richard ContrerasDepartment of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles Ave, 5th Floor, Pasadena, CA 91101, United States.
Bruno LewinDepartment of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles Ave, 5th Floor, Pasadena, CA 91101, United States.
Vennis HongDepartment of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles Ave, 5th Floor, Pasadena, CA 91101, United States.
Lei QianDepartment of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles Ave, 5th Floor, Pasadena, CA 91101, United States.
Kimberly J HolmquistDepartment of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles Ave, 5th Floor, Pasadena, CA 91101, United States.
Bing HanDepartment of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles Ave, 5th Floor, Pasadena, CA 91101, United States.
Stanley XuDepartment of Research & Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles Ave, 5th Floor, Pasadena, CA 91101, United States; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA 91101, United States.

Funding

A risk-varying and perturbed self-controlled case series design for assessing the safety of COVID-19 vaccines in a large health care systemR01AI168209 · NIAID · KAISER FOUNDATION RESEARCH INSTITUTE · PI XU, STANLEY · 2022 to 2025
$2.7M
NIAID NIH HHS R01 AI168209
6 · The paper itself

Abstract

Vaccination with updated COVID-19 vaccines is important to maintain protection against circulating SARS-CoV-2 variants. We developed and validated a prediction model for non-receipt of updated COVID-19 vaccines at Kaiser Permanente Southern California. Of 3,287,287 adults, 20.2 % received 2023-2024 COVID-19 vaccine. We assessed the association of 15 variables available in electronic health records with non-receipt of 2023-2024 updated COVID-19 vaccine. The cohort was split into development and validation samples. Performance of the 15-variable model in the development sample was moderate, with a scaled Brier score of 35.6 %, R

Indexed as

COVID-19COVID-19 VaccinesAdultAgedCaliforniaElectronic Health RecordsFemaleHumansMaleMiddle AgedSARS-CoV-2VaccinationCOVID-19 VaccinesCOVID-19 vaccinePrediction modelUptake

Identifiers

PMID40215705
PMCPMC13401481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.